The Comparative Safety of Epirubicin and Cyclophosphamide Versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial

The ELEGANT trial was a phase III study that compared the safety of epirubicin and cyclophosphamide (EC) versus docetaxel and cyclophosphamide (TC) in 275 patients with lymph node-negative, HR-positive, HER2-negative breast cancer. The study found no significant difference in disease-free survival between the two groups. However, EC was associated with higher rates of adverse events such as nausea/vomiting, hair loss, and nail changes compared to TC. Grade 3-4 neutropenia rates were similar, but all-grade neutropenia was more common in the EC group. The trial concluded that while both regimens had similar efficacy, their differing safety profiles should be considered when choosing a treatment.